Glucose Dysregulation as a Driver of Autoimmune Mimicry, Inflammation, and Psychiatric Symptoms: A Narrative Review

Glycemic control influences a wide range of psychiatric and physiological symptoms. Many psychiatric conditions are linked to poor glucose regulation. Anti-nuclear antibodies (ANAs), widely used to screen for autoimmune disease, may sometimes reflect transient metabolic immune activation rather than chronic pathology. Evidence suggests that glucose dysregulation, including glycemic variability, reactive hypoglycemia, and postprandial spikes, can trigger systemic inflammation, neuropsychiatric symptoms, and temporary autoantibody production. This review explores how these metabolic phenomena complicate diagnosis and may contribute to misclassification or overtreatment.

We conducted a narrative literature review prioritizing studies on immune activation, psychiatric outcomes, metabolic measures (including continuous glucose monitoring), and therapeutic interventions. Articles from the last ten years were emphasized, with older foundational studies included when relevant.

Metabolic instability drives immune dysregulation through macrophage polarization, mitochondrial dysfunction, oxidative stress, and impaired clearance of apoptotic debris. Glycemic variability correlates with increased inflammatory cytokines, autonomic dysfunction, and psychiatric symptoms such as anxiety, depression, and cognitive impairment. Emerging evidence from small studies suggests that correcting glucose abnormalities may reduce metabolic dysfunction and improve neuropsychiatric symptoms.

Recognizing glucose dysregulation as a contributor to autoimmune-like and psychiatric symptoms may refine diagnostic and therapeutic approaches. Incorporating a dynamic holistic approach, which in practice includes metabolic assessments, dietary interventions, use of continuous glucose monitoring, and history of blood sugar instability, into rheumatologic and psychiatric evaluations could improve diagnostic precision, reduce unnecessary immunosuppression, and enhance patient outcomes.